Syntax Stratified MidCap ETF (ARCA: SMDY)

Latest news for Syntax Stratified MidCap ETF (ARCA:SMDY)

Technology

Consumer Cyclical

Healthcare

Financial Services

Industrials

Consumer Defensive

Real Estate

Basic Materials

Communication Services

Energy

Utilities

Other

The Fund employs a replication strategy, which means that the Fund typically invests in substantially all of the securities represented in the Index in approximately the same proportions as the Index. Under normal market conditions, the Fund invests substantially all, and at least 95 Percent, of its total assets in the securities comprising the Index. The Fund will provide shareholders with at least 60 days notice prior to any material change in this 95 Percent investment policy.

Coty Inc. Class A

Scotts Miracle-Gro Company

Lumentum Holdings Inc

Frontier Communications Corp

Ciena Corp

Iridium Communications Inc

Healthcare Realty Trust Incorporated

Ziff Davis Inc

Doximity, Inc.

Qualys Inc

Syntax Stratified MidCap ETF

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $55 to $54.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $54

S&amp;T Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBA#NASDAQ">STBA</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.74 by 20.27 percent. This is unchanged from the same period last year. The company reported quarterly sales of $96.90 million which beat the analyst consensus estimate of $96.32 million by 0.60 percent. This is a 5.29 percent decrease over sales of $102.31 million the same period last year.

Earnings

Earnings Beats

STBA

S&T Bancorp Q2 EPS $0.89 Beats $0.74 Estimate, Sales $96.90M Beat $96.32M Estimate

Stephens &amp; Co. analyst Andrew Terrell maintains WaFd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFD#NASDAQ">WAFD</a>) with a Equal-Weight and raises the price target from $32 to $36.

WAFD

Stephens & Co. Maintains Equal-Weight on WaFd, Raises Price Target to $36

Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/markets/asia/24/07/39832197/apple-nvidia-supplier-tsmc-reports-strong-q2-results-amid-booming-demand-for-ai-chips-guides-q3-abov">strong quarterly report </a>lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session.
A few Fed speeches scheduled for the day, and key economic data, including jobless claims, the results of a regional manufacturing survey, and leading economic index may influence trading direction. Traders may also pay attention to the European Central Bank&#8217;s rate decision and its monetary policy outlook.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.40%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.15%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.13%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.03%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.18% to $557.94 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) added 0.41% to $483.74, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
Geopolitical concerns and apprehensions around the health of the tech reporting season weighed down on the market on Wednesday. The Nasdaq Composite and the S&amp;P 500 Index languished deep in the red throughout the session and ended notably lower, snapping a three-session winning streak. The former had its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39831761/as-trump-biden-tough-geopolitical-talk-razes-tech-stocks-munster-warns-of-ai-progre">worst one-day performance</a> since December 2022 and settled below the psychological 18,000 barrier for the first time since July 1.
Among S&amp;P 500 sectors, IT stocks fell the most, while communication services and consumer discretionary stocks also came under significant selling pressure. On the other hand, strength in healthcare, financial, energy, and consumer staple stocks mitigated some of the weaknesses.
The 30-stock Dow Industrials Average bucked the downtrend and rose for the sixth straight session, with Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) leading the charge following the pharma giant&#8217;s earnings release. Small-caps, however, retreated from a 2-1/2 year high.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.77%</td>
<td>17,996.92</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-1.39%</td>
<td>5,588.27</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.59%</td>
<td>41,198.08</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.06%</td>
<td>2,239.67</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Morgan Stanley Chief U.S. Economist Ellen Zentner said despite investor worries over economic data, the firm expects a soft landing for the U.S. economy. The firm expects three rate cuts, each 25 basis points, beginning in September. &#8220;However, increased labor market softness could prompt the Fed to bigger cuts to head off a recession,&#8221; she said.
Upcoming Economic Data:
<ul>
<li>The Labor Department is scheduled to release its jobless claims report at 8:30 a.m. EDT. Economists, on average, expect the number of individuals claiming unemployment benefits to come in at 229,000 in the week ended July 13, up from 222,000 in the previous week.</li>
<li>The Philadelphia Fed will release the results of its July regional manufacturing survey at 8:30 a.m. EDT. The consensus estimate calls for a reading of 2.9 for the headline diffusion index of business activity, up from 1.3 in June.</li>
<li>The Conference Board is due to release the leading economic index for June at 10 a.m. EDT. The index is expected to show a 0.3% drop in the index, not as worse as the 0.5% fall in May.</li>
<li>Chicago Fed President Austan Goolsbee will speak at 10 a.m. EDT, Dallas Fed President Lorie Logan at 1:45 p.m. EDT, San Francisco Fed President Mary Daly at 6:05 p.m. EDT, and Fed Governor Michelle Bowman at 7:45 P.m. EDT.</li>
<li>The Treasury will auction four- and eight-week bills at 11:30 a.m. EDT and 10-year TIPS auction at 1 p.m. EDT.</li>
</ul>
See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Stocks In Focus:
<ul>
<li>Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) rose over 1% <a href="https://www.benzinga.com/premarket">in premarket trading</a> trading following the aluminum maker&#8217;s quarterly report. Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) fell over 2.50% and SL Green Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) gained over 3%.</li>
<li>Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) plunged over 10% on a slight revenue miss.</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>), Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>), Marsh &amp; McLennan Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>), D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) are among the <a href="https://www.benzinga.com/calendars/earnings">notable companies reporting their quarterly results ahead of the market open.</a></li>
<li>Those reporting after the close include Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were modestly lower, while gold futures rose. The 10-year Treasury yield climbed 4.2 points to 4.185%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slipped below the $65,000 level.
The Asian markets had a mixed session, with Japan falling on weak trade data and Taiwanese and South Korean markets extending their slide. On the other hand, the Australian, Chinese, and Hong Kong markets ended in the green.
On the other hand, European stocks firmed up ahead of the rate decision. The European Central Bank is scheduled to announce its rate decision at 8:15 a.m. EDT, with economists anticipating that the bank will hold fire after reducing rates by 25 basis points at the last meeting.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39766859/netflix-goldman-sachs-j-j-asml-lead-q2-reports-this-week-as-analysts-see-earnings-growth-accelerati">Netflix, Goldman Sachs, J&amp;J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years</a></li>
</ul>
Image generated using Midjourney

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

ISRG

NFLX

Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens

Piper Sandler analyst Mark Lear maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and raises the price target from $247 to $249.

FANG

Piper Sandler Maintains Overweight on Diamondback Energy, Raises Price Target to $249

Guidance

Manpower Sees Q3 EPS Of $1.25 - $1.35 Vs. $1.36 Est.

Berkshire Hills Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.52 by 9.62 percent. This is a 3.64 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $88.53 million which missed the analyst consensus estimate of $90.50 million by 2.17 percent. This is a 4.56 percent decrease over sales of $92.76 million the same period last year.

Earnings Misses

BHLB

Berkshire Hills Bancorp Q2 Adj $0.57 Beats $0.52 Estimate, Sales $88.53M Miss $90.50M Estimate

Stephens &amp; Co. analyst Terry McEvoy maintains Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) with a Equal-Weight and raises the price target from $39 to $45.

EQBK

Stephens & Co. Maintains Equal-Weight on Equity Bancshares, Raises Price Target to $45

BWMN

Bowman Acquires FCS Group, Terms Not Disclosed; Co. Anticipates Deal Will Initially Contribute Annualized Net Service Billing Run Rate Of ~$7M And Be Immediately Accretive

Abbott Laboratories Q2 2024 Adj EPS $1.14 Beats $1.10 Estimate, Sales $10.377B Beat $10.371B Estimate

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $46 to $47.

Piper Sandler Maintains Overweight on EQT, Raises Price Target to $47

ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.28 by 1.56 percent. This is a 17.72 percent decrease over earnings of $1.58 per share from the same period last year. The company reported quarterly sales of $4.52 billion which met the analyst consensus estimate. This is a 6.92 percent decrease over sales of $4.86 billion the same period last year.

ManpowerGroup Q2 Adj $1.30 Beats $1.28 Estimate, Sales $4.52B Inline

OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.96 by 12.5 percent. This is a 16.13 percent increase over earnings of $0.93 per share from the same period last year.

OFG Bancorp Q2 2024 GAAP EPS $1.08 Beats $0.96 Estimate

Market-Moving Exclusives

Exclusives

LSTA

EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and raises the price target from $233 to $234.

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Raises Price Target to $234

Haystack Oncology, a Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>).
Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules.
Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors.
Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
In the FORTIFIDE study, Lisata is investigating the safety, tolerability, and efficacy of its lead product candidate, certepetide, when given as a 4-hour continuous infusion in combination with standard-of-care treatment in subjects with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX, a treatment for pancreatic cancer.
As part of this research, Lisata has engaged Haystack to use its MRD technology to measure serum ctDNA levels at multiple time points in patients throughout the study as an exploratory endpoint for analyzing the early therapeutic effect of certepetide.
The American Cancer Society estimates more than 66,000 individuals nationwide will be diagnosed with pancreatic cancer in 2024. mPDAC accounts for more than 90% of pancreatic cancer cases and is a highly aggressive form of the disease.
Most recently, Lisata Therapeutics announced the early completion of enrollment in its Phase 2a BOLSTER trial evaluating certepetide (formerly LSTA1), Lisata&#8217;s investigational product, as a treatment for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39790403/lisata-therapeutics-announces-completion-of-enrollment-in-its-phase-2a-bolster-trial-of-certepetid" rel="noreferrer noopener">first-line cholangiocarcinoma</a>.
Price Action: DGX shares closed at $148.48, and LSTA shares closed at $3.66 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/05/38842564/employers-struggle-with-drug-test-policies-amid-varying-state-laws-cheating-on-drug-tests-reaches-30" target="_blank" rel="noreferrer noopener">Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High</a>.</li>
</ul>

Biotech

Health Care

Contracts

General

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Stephens &amp; Co. analyst Terry McEvoy maintains Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) with a Equal-Weight and raises the price target from $90 to $110.

Stephens & Co. Maintains Equal-Weight on Nicolet Bankshares, Raises Price Target to $110

Lilium N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares are trading higher after it entered into a definitive sales agreement with Saudia Group or 50 Lilium Jets, with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39832573/saudia-group-signs-industry-leading-sales-agreement-with-lilium-to-acquire-up-to-100-evtol-jets" rel="noreferrer noopener">options for an additional 50 aircraft</a>.
Following the Memorandum of Understanding signed between Saudia Group and Lilium in October 2022, this sales agreement represents a significant milestone in the industry.
The deal marks the largest reported firm order of eVTOL aircraft in the MENA region by an airline committed to operating these aircraft.
The agreement details payment schedules, delivery timelines, performance guarantees, and provisions for spare parts and maintenance.
Additionally, the parties aim to finalize a &#8220;Lilium POWER-ON&#8221; agreement for fleet maintenance and support.
Saudia Group anticipates receiving its first jets in 2026, managed by its subsidiary, Saudia Private.
Lilium&#8217;s agreement with Saudia Group expands its order pipeline, comprising 106 firm orders and reservations, 76 options, and around 600 aircraft under MOU.
H.E. Engr. Ibrahim Al-Omar, Director General of Saudia Group,&nbsp;said,&nbsp;&#8220;This agreement amplifies our commitment to the Saudi Vision 2030 and is the result of a collaborative effort over the past years between Lilium and Saudia Group to explore how we can best bring eVTOL to the skies of Saudi Arabia.&#8221;
&#8220;Business travelers and exhibition attendees will benefit tremendously from the ease and speed of electric aircraft, allowing them to seamlessly attend and participate in events. These innovative vehicles will also be a game-changer for tourism, sports, and entertainment, offering a premium travel experience for these exciting destinations.&#8221;
Lilium is also in advanced discussions with global airlines committed to reducing carbon emissions and adopting electric regional air travel.
Yesterday, Lilium confirmed its 2026 delivery schedule for the first customer shipments, following a recent program review that includes testing, validation, and preparations for the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39812459/lilium-reaffirms-2026-target-for-first-customer-deliveries-and-provides-additional-detail-on-testi" rel="noreferrer noopener">first manned flight in early 2025</a>.
Price Action: LILM shares are up 2.98% at $0.9999 premarket at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Small Cap

LILM

Why Electric Aircraft Manufacturer Lilium Shares Are Surging Premarket Thursday

Piper Sandler analyst Mark Lear maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and raises the price target from $33 to $34.

Piper Sandler Maintains Neutral on APA, Raises Price Target to $34

JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and lowers the price target from $24 to $21.

RLAY

JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21

Sentiment Can Change... Fast

Why Quality Matters, Even If Markets Are At Record Highs

U.S. Stocks Look Overbought. Will It Matter (Anytime Soon)?

Q2 2024 Earnings Season Preview - The S&P 500 Breaks Records Ahead Of Bank Reports

S&P 500 Reaches New Heights As Likelihood Of Q3 2024 Rate Cut Rises

The Curse Of The Mega Caps

Why We Keep Leaning Into Risk

Brad Simpson On Why Geopolitics, Not Central Banks, Are In Focus And What It Means For Markets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Syntax Stratified MidCap ETF

News

Latest news for Syntax Stratified MidCap ETF (ARCA:SMDY)